gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Platelet-derived growth factor receptor, beta polypeptide

This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. This gene is flanked on chromosome 5 by the genes for granulocyte-macrophage colony-stimulating factor and macrophage-colony stimulating factor receptor; all three genes may be implicated in the 5-q syndrome. A translocation between chromosomes 5 and 12, that fuses this gene to that of the translocation, ETV6, leukemia gene, results in chronic myeloproliferative disorder with eosinophilia. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KDR, CAN, EGFR, Akt, HAD
Papers using PDGFR antibodies
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.
Carvalho Luzia Helena, In PLoS ONE, 2008
... Antibodies to p-STAT3, STAT3, p-ERK1/2, ERK1/2, p-EGFR, p-PDGFR-beta, PDGFR-beta, p-p65NF-kappaB, p65NF-kappaB were purchased from Cell Signaling Technology (Danvers, MA) ...
Divergent optimum levels of lycopene, beta-carotene and lutein protecting against UVB irradiation in human fibroblastst
Wu Wen-Bin et al., In Journal of Biomedical Science, 2001
... Antibodies (Abs) raised against phospho-ERK1/2 and PDGFR-β were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) ...
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma
Huynh H et al., In British Journal of Cancer, 2001
... cyclin A, cdk-2, cdk-4, cdk-6, p27, Bax, Bad, Bcl-xL, Mcl-1, survivin, ERK1/2, VEGFR-2, phospho-VEGFR-2 Tyr951, phospho-PDGFR-β Tyr1021, and α-tubulin were from Santa Cruz Biotechnology Inc ...
Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1
Scita Giorgio et al., In The Journal of Cell Biology, 1998
... ); rabbit polyclonals anti–Sos-1; anti-PDGFR α and β (Santa Cruz Biotechnology, Inc.); monoclonal anti–phosphotyrosine, polyclonal ...
LIGAND: A versatile computerized approach for characterization of ligand binding systems.
Simon Eric J et al., In BMC Pharmacology, 1979
... ), and the PDGFR antagonist, tyrosphostin, 9 were purchased from Biomol (Plymouth Meeting, PA) ...
Papers on PDGFR
Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor.
Cheung et al., Salt Lake City, United States. In J Vasc Res, Feb 2016
RESULTS: In an in vivo porcine model, PDGF, VEGF and their receptors PDGFR-α and VEGFR-2 were upregulated at the venous anastomosis within 2 weeks after AVG placement, with NH development by 4 weeks.
Role of pericytes in angiogenesis: focus on cancer angiogenesis and anti-angiogenic therapy.
Hu et al., In Neoplasma, Feb 2016
Although current studies indicate that PDGF/PDGFR-β, Ang/Tie2, TGF-β involve in the regulation of pericytes recruitment, the mechanisms governing pericytes migration and regulating angiogenesis, especially in cancers, have not been fully clear.
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Gemma et al., Tokyo, Japan. In Int J Oncol, Feb 2016
No correlations between FGFR, PDGFR and VEGFR family activation and sensitivity to nintedanib were found.
Expression and significance of Ku80 and PDGFR-α in nasal NK/T-cell lymphoma.
Zhong et al., Davao, Philippines. In Pathol Res Pract, Jan 2016
BACKGROUND: To investigate the clinical and prognostic significance of Ku80 and PDGFR-α in nasal type NK/T cell lymphoma (NKTCL).
Combinatorial Treatment with Apelin-13 Enhances the Therapeutic Efficacy of a Preconditioned Cell-Based Therapy for Peripheral Ischemia.
Hamano et al., Ube, Japan. In Sci Rep, Dec 2015
Apelin-13 upregulated expression of PDGF-BB and TGF-β1 in hypoxic PBMNCs, as well as that of PDGFR-β in vascular smooth muscle cells (VSMCs).
Endometrial stem/progenitor cells: the first 10 years.
Deane et al., Australia. In Hum Reprod Update, Dec 2015
Specific markers for their enrichment have been identified, CD146(+)PDGFRβ(+) (platelet-derived growth factor receptor beta) and SUSD2(+) (sushi domain containing-2), which detected their perivascular location and likely pericyte identity in endometrial basalis and functionalis vessels.
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Tsatsoulis et al., Ioánnina, Greece. In Trends Endocrinol Metab, Nov 2015
For example, inhibition of Abelson tyrosine kinase (c-Abl) results in β cell survival and enhanced insulin secretion, while platelet-derived growth factor receptor (PDGFR) and epidermal growth factor receptor (EGFR) inhibition leads to improvement in insulin sensitivity.
World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management.
Gotlib, Stanford, United States. In Am J Hematol, Nov 2015
After evaluation of secondary causes of eosinophilia, the 2008 World Health Organization establishes a semi-molecular classification scheme of disease subtypes including 'myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1', chronic eosinophilic leukemia, not otherwise specified, (CEL, NOS), lymphocyte-variant hypereosinophilia, and idiopathic hypereosinophilic syndrome (HES), which is a diagnosis of exclusion.
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Kristeleit et al., Los Angeles, United States. In Lancet Oncol, Jun 2015
We assessed the safety and activity of dovitinib, a potent tyrosine-kinase inhibitor of fibroblast growth factor receptors, VEGF receptors, PDGFR-β, and c-KIT, as second-line therapy both in patients with FGFR2-mutated (FGFR2(mut)) endometrial cancer and in those with FGFR2-non-mutated (FGFR2(non-mut)) endometrial cancer.
Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export.
Coppola et al., Los Angeles, United States. In Nat Genet, Jun 2015
Primary familial brain calcification (PFBC) is a neurological disease characterized by calcium phosphate deposits in the basal ganglia and other brain regions and has thus far been associated with SLC20A2, PDGFB or PDGFRB mutations.
A continuous molecular roadmap to iPSC reprogramming through progression analysis of single-cell mass cytometry.
Nolan et al., Stanford, United States. In Cell Stem Cell, Apr 2015
Ki67(low) cells from this intermediate population reverted to a MEF-like phenotype, but Ki67(high) cells advanced through the M-E-T and then bifurcated into two distinct populations: an ESC-like Nanog(high)Sox2(high)CD54(high) population and a mesendoderm-like Nanog(low)Sox2(low)Lin28(high)CD24(high)PDGFR-α(high) population.
Endophilin marks and controls a clathrin-independent endocytic pathway.
McMahon et al., Cambridge, United Kingdom. In Nature, Feb 2015
This pathway mediates the ligand-triggered uptake of several G-protein-coupled receptors such as α2a- and β1-adrenergic, dopaminergic D3 and D4 receptors and muscarinic acetylcholine receptor 4, the receptor tyrosine kinases EGFR, HGFR, VEGFR, PDGFR, NGFR and IGF1R, as well as interleukin-2 receptor.
Potential Therapeutic Targets in Uterine Sarcomas.
Amant et al., Leuven, Belgium. In Sarcoma, 2014
Currently, the only targeted therapy approved in leiomyosarcoma patients is pazopanib, a multitargeted inhibitor blocking VEGFR, PDGFR, FGFR, and c-KIT.
Overview of fundamental study of pazopanib in cancer.
Zhou et al., Tianjin, China. In Thorac Cancer, 2014
Through the exploration of inhibitors of vascular endothelial growth factor receptor (VEGFR)-2, deemed as the major angiogenesis pathway, pazopanib was found as a small molecular pan-VEGFR and pan-platelet-derived growth factor receptor (PDGFR) inhibitor, with suitable pharmacodynamic and pharmacokinetic parameters to be an oral drug.
Incorporation of pazopanib in maintenance therapy of ovarian cancer.
Harter et al., Angola. In J Clin Oncol, 2014
PURPOSE: Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR) -α/-β, and c-Kit.
Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression.
Liebner et al., Frankfurt am Main, Germany. In J Exp Med, 2012
beta-catenin transcriptional activity directly regulated endothelial expression of platelet-derived growth factor B, leading to mural cell recruitment thereby contributing to vascular quiescence
Hydrophobic matching controls the tilt and stability of the dimeric platelet-derived growth factor receptor (PDGFR) β transmembrane segment.
Ulrich et al., Karlsruhe, Germany. In J Biol Chem, 2012
there exists a pronounced interplay between the platelet-directed growth factor receptor beta transmembrane segment and the lipid bilayer thickness
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity.
Rich et al., Cleveland, United States. In Genes Dev, 2012
Study found that PDGFRalpha is expressed only in a subset of proneural glioblastoma , while PDGFRbeta is more commonly expressed in tumors but is preferentially expressed by self-renewing tumorigenic GBM stem cells.
Blockade of PDGFR-β activation eliminates morphine analgesic tolerance.
Gutstein et al., Houston, United States. In Nat Med, 2012
we show that platelet-derived growth factor receptor-beta (PDGFR-beta)-mediated signaling plays a key role in morphine tolerance.
PDGF-D/PDGF-ββ receptor-regulated chemotaxis of malignant mesothelioma cells.
Nishizaki et al., Nishinomiya, Japan. In Cell Physiol Biochem, 2011
PDGF-D promotes malignant mesothelioma cell chemotaxis through PDGF-betabeta receptor signaling pathways along a PI3 kinase/PDK1/Akt/Rac1/ROCK axis and relevant to ERK activation
share on facebooktweetadd +1mail to friends